Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

Bamlanivimab-etesevimab and casirivimab-imdevimab are authorized by the US Food and Drug Administration for emergency treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk persons. There has been no study comparing their clinical efficacy. In this retrospective study of 681...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Horo, John, Challener, Douglas W., Anderson, Ryan J., Arndt, Richard F., Ausman, Sara E., Hall, Scott T., Heyliger, Alexander, Kennedy, Brian D., Sweeten, Perry W., Ganesh, Ravindra, Razonable, Raymund R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mayo Foundation for Medical Education and Research 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864104/
https://www.ncbi.nlm.nih.gov/pubmed/35512884
http://dx.doi.org/10.1016/j.mayocp.2022.02.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864104/
https://www.ncbi.nlm.nih.gov/pubmed/35512884
http://dx.doi.org/10.1016/j.mayocp.2022.02.009

Ejemplares similares